CR Sanjiu(SZ:000999) Zheng Quan Shi Bao Wang·2024-11-20 09:16Core Insights - The State-owned Assets Supervision and Administration Commission recognized China Resources Sanjiu as a "benchmark" enterprise for the second consecutive year, highlighting its leadership in the pharmaceutical sector among 349 "demonstration enterprises" [1] - The company aims to enhance its core competitiveness and innovation capabilities while contributing to the high-quality development of the traditional Chinese medicine industry [1] Group 1: Strategic Development - China Resources Sanjiu has established a clear development strategy focused on becoming a leader in the public health and pharmaceutical industry, systematically strengthening its core pharmaceutical business [2] - The company has divested non-core businesses such as food and pharmaceutical distribution, while increasing the proportion of pharmaceutical manufacturing in its revenue structure through strategic acquisitions [2] - Since 2012, the company has successfully completed over 10 acquisitions, including Auno Pharmaceutical and Kunming Pharmaceutical Group, to build competitive advantages in chronic disease management and children's health [2][3] Group 2: Innovation and R&D - The company has built a "pyramid-type" innovation system, enhancing its research and development capabilities and establishing a project management system that covers the entire lifecycle of innovation [5][6] - In 2023, the company invested 889 million yuan in R&D, a 78.61% increase from 2018, with 778 R&D personnel, reflecting a 126.16% growth over the same period [6] - The company has achieved breakthroughs in various therapeutic areas, including oncology and respiratory diseases, and has received national recognition for its contributions to traditional Chinese medicine [6] Group 3: Digital Transformation and Smart Manufacturing - China Resources Sanjiu is actively promoting digital transformation across its operations, including production management and supply chain, to enhance efficiency and quality control [7][8] - The company plans to establish multiple smart manufacturing benchmark factories to advance the modernization of traditional Chinese medicine [8] - The vision of the company is to become a leader in the public health industry, focusing on high-quality pharmaceutical product innovation and smart manufacturing [8]